MA46061A - Traitement ascaroside de maladies auto-immunes et inflammatoires - Google Patents
Traitement ascaroside de maladies auto-immunes et inflammatoiresInfo
- Publication number
- MA46061A MA46061A MA046061A MA46061A MA46061A MA 46061 A MA46061 A MA 46061A MA 046061 A MA046061 A MA 046061A MA 46061 A MA46061 A MA 46061A MA 46061 A MA46061 A MA 46061A
- Authority
- MA
- Morocco
- Prior art keywords
- ascaroside
- autoimmune
- treatment
- inflammatory diseases
- inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379651P | 2016-08-25 | 2016-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46061A true MA46061A (fr) | 2019-07-03 |
Family
ID=61245393
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046061A MA46061A (fr) | 2016-08-25 | 2017-08-25 | Traitement ascaroside de maladies auto-immunes et inflammatoires |
| MA046062A MA46062A (fr) | 2016-08-25 | 2017-08-25 | Traitement par ascaroside de l'oesophagite à éosinophiles |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046062A MA46062A (fr) | 2016-08-25 | 2017-08-25 | Traitement par ascaroside de l'oesophagite à éosinophiles |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US11077151B2 (fr) |
| EP (2) | EP3503904B1 (fr) |
| CN (1) | CN109843309A (fr) |
| MA (2) | MA46061A (fr) |
| WO (2) | WO2018039591A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107417745A (zh) | 2011-08-08 | 2017-12-01 | 加州理工学院 | 线虫小分子的应用 |
| WO2018039591A1 (fr) | 2016-08-25 | 2018-03-01 | California Institute Of Technology | Traitement ascaroside de maladies auto-immunes et inflammatoires |
| WO2020236621A1 (fr) | 2019-05-17 | 2020-11-26 | California Institute Of Technology | Dérivés d'ascaroside et procédés d'utilisation |
| US20220264876A1 (en) * | 2019-07-08 | 2022-08-25 | Boyce Thompson Institute For Plant Research, Inc. | Compositions and methods for enhancing plant growth |
| MX2023001492A (es) * | 2020-08-06 | 2023-03-08 | Bioverativ Usa Inc | Citocinas inflamatorias y fatiga en sujetos con una enfermedad mediada por el complemento. |
| CN113475629A (zh) * | 2021-08-12 | 2021-10-08 | 广东省科学院动物研究所 | 蛔甙在制备提高S.carpocapsae All线虫产量制剂中的应用 |
| CN113575770A (zh) * | 2021-08-12 | 2021-11-02 | 广东省科学院动物研究所 | 蛔甙在制备促进S.carpocapsae All感染期线虫恢复发育制剂中的应用 |
| CN113796460B (zh) * | 2021-08-19 | 2023-07-18 | 云南省烟草公司玉溪市公司 | 蛔甙在制备促进H.indica LN2感染期线虫恢复发育制剂中的应用 |
| CN113728978A (zh) * | 2021-08-19 | 2021-12-03 | 云南省烟草公司玉溪市公司 | 蛔甙在制备H.bacteriophora H06感染期线虫恢复发育制剂中的应用 |
| US20250287946A1 (en) * | 2022-04-29 | 2025-09-18 | Ascribe Bioscience Inc. | Modified release of ascarosides |
| AR133343A1 (es) * | 2023-07-25 | 2025-09-17 | Ascribe Bioscience Inc | Combinaciones de nutrientes vegetales y ascarósidos y métodos para su uso |
| CN119606992A (zh) * | 2024-04-25 | 2025-03-14 | 中国科学院动物研究所 | 蛔甙在制备治疗与肥胖相关的疾病的药物中的用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1018396A (en) | 1911-08-07 | 1912-02-20 | Oley L Ledington | Culvert-mold. |
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| TW327125B (en) | 1994-02-07 | 1998-02-21 | Merck & Co Inc | Composition and method for protecting against pine exhausted |
| WO1996019920A1 (fr) | 1994-12-27 | 1996-07-04 | Pfizer Pharmaceuticals Inc. | Compositions utilisees pour traiter les infections des arbres par les nematodes |
| ATE391492T1 (de) | 1997-07-29 | 2008-04-15 | Alcon Lab Inc | Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat |
| EP1051167A1 (fr) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Utilisations pharmaceutiques de (-)-bupropion optiquement pur |
| US6444686B1 (en) | 1998-12-18 | 2002-09-03 | Brsitol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| DE10163602A1 (de) | 2001-12-21 | 2003-07-10 | Alpha Biocare Gmbh Gebaeude 26 | Mittel mit Nematoden und Plathelminthen zur Behandlung allergischer Erkrankungen |
| KR100700884B1 (ko) | 2002-11-14 | 2007-03-29 | 백융기 | 약학적으로 유용한 노화 및 스트레스 조절용 신규 페로몬 화합물 및 그 분리정제방법 |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| ES2593113T3 (es) | 2003-08-07 | 2016-12-05 | Allergan, Inc. | Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| KR100556335B1 (ko) | 2004-02-05 | 2006-03-03 | 정만길 | 6알-(3,6-디데옥시-엘-아라비노-헥소피라노실옥시)헵타노익산, 그 제조방법 및 그를 포함하는 장기휴면 유발효과 |
| AU2005244126B2 (en) | 2004-05-11 | 2011-05-12 | Bayer Cropscience Lp | Method of controlling termites |
| DE102006056544A1 (de) | 2006-11-29 | 2008-06-05 | Bayer Cropscience Ag | Insektizide Wirkstoffkombinationen (Formononetin+Insektizide) |
| EA200901143A1 (ru) | 2007-03-01 | 2010-04-30 | Басф Се | Пестицидные активные смеси, включающие аминотиазолиновые соединения |
| US8318146B1 (en) | 2008-02-01 | 2012-11-27 | The United States Of America, As Represented By The Secretary Of Agriculture | Ascarosides as nematode sex pheromones |
| CN104356177A (zh) | 2008-02-12 | 2015-02-18 | 陶氏益农公司 | 杀虫组合物 |
| KR20090088496A (ko) | 2008-02-15 | 2009-08-20 | 연세대학교 산학협력단 | 6-(3,6-디데옥시-α-L-아라비노-헥소피라노실옥시)헵타노익산 유도체 및 그 제조 방법 |
| US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| GB0823309D0 (en) | 2008-12-19 | 2009-01-28 | Univ Bath | Functionalising reagents and their uses |
| KR101210553B1 (ko) | 2010-06-09 | 2012-12-10 | 연세대학교 산학협력단 | 신규한 당지질 유도체 화합물 및 이를 함유하는 혈관평활근세포 이상 증식 억제용 조성물 |
| WO2011163614A2 (fr) * | 2010-06-24 | 2011-12-29 | Meritage Pharma, Inc. | Méthodes de traitement de l'inflammation œsophagienne |
| EP2707379A4 (fr) | 2011-05-13 | 2014-10-08 | Glycosyn LLC | Utilisation de 2'-fucosyllactose, 3-fucosyllactose et lactodifucotétraose purifiés en tant que prébiotiques |
| US9445596B2 (en) | 2011-08-08 | 2016-09-20 | California Institute Of Technology | Small molecule compounds for the control of nematodes |
| CN107417745A (zh) | 2011-08-08 | 2017-12-01 | 加州理工学院 | 线虫小分子的应用 |
| WO2013039872A1 (fr) | 2011-09-12 | 2013-03-21 | Tufts Medical Center | Compositions et procédés pour le traitement de maladies inflammatoires de l'intestin |
| LT3091029T (lt) * | 2011-10-31 | 2023-02-27 | F. Hoffmann-La Roche Ag | Anti-il13 antikūno kompozicijos |
| WO2014151648A1 (fr) | 2013-03-15 | 2014-09-25 | Coronado Biosciences, Inc. | Traitement d'une maladie auto-immune au moyen de parasites helminthiques |
| US10136595B2 (en) | 2013-03-15 | 2018-11-27 | Boyce Thompson Institute For Plant Research, Inc. | Compositions and methods for modulating immunity in plants |
| CN105263324B (zh) * | 2013-03-15 | 2020-02-11 | 博伊斯汤普生植物研究所 | 用于调节植物免疫的组合物和方法 |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| WO2018039591A1 (fr) | 2016-08-25 | 2018-03-01 | California Institute Of Technology | Traitement ascaroside de maladies auto-immunes et inflammatoires |
| WO2020236621A1 (fr) | 2019-05-17 | 2020-11-26 | California Institute Of Technology | Dérivés d'ascaroside et procédés d'utilisation |
| US20220409650A1 (en) | 2019-06-03 | 2022-12-29 | Holoclara, Inc. | Compositions and methods for ascaroside modification of mammalian microbiota |
-
2017
- 2017-08-25 WO PCT/US2017/048665 patent/WO2018039591A1/fr not_active Ceased
- 2017-08-25 MA MA046061A patent/MA46061A/fr unknown
- 2017-08-25 CN CN201780061366.1A patent/CN109843309A/zh active Pending
- 2017-08-25 WO PCT/US2017/048672 patent/WO2018039593A1/fr not_active Ceased
- 2017-08-25 US US16/327,659 patent/US11077151B2/en active Active
- 2017-08-25 EP EP17844508.6A patent/EP3503904B1/fr active Active
- 2017-08-25 US US16/327,670 patent/US11464810B2/en active Active
- 2017-08-25 EP EP17844507.8A patent/EP3503903A4/fr active Pending
- 2017-08-25 MA MA046062A patent/MA46062A/fr unknown
-
2021
- 2021-07-30 US US17/390,096 patent/US20220016182A1/en active Pending
-
2022
- 2022-09-09 US US17/941,589 patent/US20230026686A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220016182A1 (en) | 2022-01-20 |
| US20190192578A1 (en) | 2019-06-27 |
| EP3503904A1 (fr) | 2019-07-03 |
| WO2018039591A1 (fr) | 2018-03-01 |
| EP3503904B1 (fr) | 2026-01-21 |
| US11077151B2 (en) | 2021-08-03 |
| EP3503904C0 (fr) | 2026-01-21 |
| US11464810B2 (en) | 2022-10-11 |
| EP3503903A4 (fr) | 2020-03-25 |
| EP3503904A4 (fr) | 2020-03-25 |
| MA46062A (fr) | 2019-07-03 |
| WO2018039593A9 (fr) | 2018-05-03 |
| EP3503903A1 (fr) | 2019-07-03 |
| CN109843309A (zh) | 2019-06-04 |
| US20190175663A1 (en) | 2019-06-13 |
| US20230026686A1 (en) | 2023-01-26 |
| WO2018039593A1 (fr) | 2018-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3503903A4 (fr) | Traitement ascaroside de maladies auto-immunes et inflammatoires | |
| IL262608A (en) | Combination treatment of ocular inflammatory disorders and diseases | |
| EP3634442A4 (fr) | Méthodes de traitement et de prévention de maladies | |
| SI3240554T1 (sl) | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni | |
| EP3658139A4 (fr) | Méthodes de traitement de maladies hépatiques | |
| EP3373962A4 (fr) | Compositions et méthodes de traitement de maladies auto-immunes et de cancers | |
| EP3397149A4 (fr) | Cartographie et traitement de tissu | |
| EP3344258A4 (fr) | Traitement de maladies auto-immunes et de maladies auto-inflammatoires | |
| EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
| EP2983791A4 (fr) | Procédés et compositions pour le traitement de maladies auto-immunes | |
| FR25C1031I1 (fr) | Traitement de maladies cholestatiques intrahepatiques | |
| IL284125A (en) | Quinoline derivatives for use in the treatment of inflammation diseases | |
| EP3273955A4 (fr) | Traitement de maladies respiratoires | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| EP3458454A4 (fr) | Nouveaux découplants mitochondriaux pour le traitement de maladies métaboliques et du cancer | |
| IL269158A (en) | Compositions and methods for treating inflammatory diseases | |
| IL262713A (en) | Cannabidiol for reducing a steroid dose and treating inflammatory and autoimmune diseases | |
| EP2945616A4 (fr) | Traitement de maladies pulmonaires | |
| EP3664789A4 (fr) | Méthodes de traitement de maladies et de lésions des nerfs | |
| EP3313417A4 (fr) | Méthodes de traitement de troubles auto-immuns et allo-immuns | |
| EP3737363A4 (fr) | Méthodes de traitement de maladies inflammatoires chroniques | |
| FR3017298B1 (fr) | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| MA53986A (fr) | Traitement de maladies neurologiques avec du zilucoplan | |
| EP3727369A4 (fr) | Test théragnostique pour le traitement antifongique de maladies inflammatoires |